Contact Information 
Address(Office)E12-4010Joong Sup Shim
Phone(Office)8822 4990
(Lab)8822 4217
Fax8822 2314
Ph.D.Dept. Bioscience & Biotechnology, Sejong University, Korea (2000-2004)
M.S.Dept. Applied Biology, Dongguk University, Korea (1998-2000)
B.S.Dept. Biology, Dongguk University, Korea (1990-1998)
2019-presentAssociate Professor, Faculty of Health Sciences, University of Macau
2013-2019Assistant Professor, Faculty of Health Sciences, University of Macau
2011-2013Research Associate, Dept. Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
2006-2011Postdoctoral Fellow, Dept. Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
2005-2006Research Scientist, Biotechnology Industrialization Institute, Yonsei University, Seoul, Korea
2004-2005Lecturer, Dept. Bioscience & Biotechnology, Sejong University, Seoul, Korea
2000-2001Research Assistant, Dept. Bioscience & Biotechnology, Sejong University, Seoul, Korea
Research Interests
[Exploiting synthetic lethality for cancer precision medicine]

Synthetic lethality is a genetic interaction where a single gene deficiency is tolerable for cell viability while the combination of deficiencies in two genes leads to cell death. The concept of the synthetic lethality has been widely exploited in cancer research field because a large portion of cancer has loss-of-function mutations in tumor suppressor genes. Synthetic lethality utilizes the mutations in tumor suppressor genes as a mark for selectivity of anticancer drugs. Pharmacological or genetic perturbation of a synthetic lethality partner of a tumor suppressor will cause selective lethality of the cancer cells that carry the tumor suppressor mutation. As it provides a strong cancer cell selectivity, synthetic lethality is one of core approaches for cancer precision medicine.

My lab is studying major tumor suppressor genes, including p53, PTEN, RB1, BRCA1, ARID1A, and SMAD4, and is expanding to newly identified tumor suppressors. We have established isogenic cell pairs for the tumor suppressor genes and actively working on identifying synthetic lethality partners using chemical and genetic screenings.

Representative Publications
  1. Wu C, Lyu J, Yang EJ, Liu Y, Zhang B, Shim JS. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat Commun, 2018, 9(1):3212.
  2. Liu Y, Yang EJ, Zhang B, Miao Z, Wu C, Lyu J, Tan K, Wong KH, Poon TCW, Shim JS. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora A kinases. Cancer Lett, 2018, S0304-3835(18)30523-8.
  3. Zhang B, Lyu J, Liu Y, Wu C, Yang EJ, Pardeshi L, Tan K, Wong KH, Chen Q, Xu X, Deng CX, Shim JS. BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition. Oncogene, 2018, doi: 10.1038/s41388-018-0408-8.
  4. Lyu J, Yang EJ, Head SA, Ai N, Zhang B, Wu C, Li RJ, Liu Y, Chakravarty H, Zhang S, Tam KY, Dang Y, Kwon HJ, Ge W, Liu JO, Shim JS. Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking. Int J Biol Sci, 2018; 14(10):1175-1185.
  5. Lyu J, Yang EJ, Head SA, Ai N, Zhang B, Wu C, Li RJ, Liu Y, Yang C, Dang Y, Kwon HJ, Ge W, Liu JO, Shim JS. Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth. Cancer Lett, 2017; 409:91-103.
  6. Head SA, Shi WQ, Yang EJ, Nacev BA, Hong SY, Pasunooti KK, Li RJ, Shim JS, Liu JO. Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis. ACS Chem Biol, 2017; 12(1):174-182.
  7. Du B and Shim JS. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules, 2016; 21(7):E965.
  8. Yang EJ, Wu C, Liu Y, Lv J, Shim JS. Revisiting non-cancer drugs for cancer therapy. Curr Top Med Chem, 2016; 16(19):2144-55.
  9. Shim JS, Li RJ, Bumpus NN, Head SA, Kumar K, Yang EJ, Lv J, Shi W, Liu JO. Divergence of anti-angiogenic activity and hepatotoxicity of different stereoisomers of itraconazole. Clin Cancer Res, 2016; 22(11):2709-20.
  10. Head SA, Shi WQ, Zhao L, Gorshkov K, Pasunooti KK, Chen Y, Deng Z, Li RJ, Shim JS, Tan W, Hartung T, Zhang J, Zhao Y, Colombini M, Liu JO. The antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci USA, 2015; 112(52):E7276-85.
  11. Wang G, Rajpurohit SK, Delaspre F, Walker SL, White DT, Ceasrine A, Kuruvilla R, Li RJ, Shim JS, Liu JO, Parsons MJ, Mumm JS. First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic β-cell mass. eLife, 2015; 10.7554/eLife.08261.
  12. Lv J and Shim JS. Existing drugs and their application in drug discovery targeting cancer stem cells. Arch Pharm Res, 2015; 38(9):1617-26.
  13. Kim NH, Pham NB, Quinn RJ, Shim JS, Cho H, Cho SM, Park SW, Kim JH, Seok SH, Oh JW, Kwon HJ. The small molecule R-(-)-β-O-methylsynephrine binds to nucleoporin 153 kDa and inhibits angiogenesis. Int J Biol Sci, 2015; 11(9):1088-99.
  14. Shim JS*, Li RJ, Lv J, Head SA, Yang EJ, Liu JO*. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Cancer Lett, 2015; 362(1):106-15.
  15. Wang M1, Shim JS1, Li RJ1, Dang Y, He Q, Das M, Liu JO. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer. Br J Pharmacol, 2014; 171(19):4478-89.
  16. Shim JS* and Liu JO*. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci, 2014; 10(7):654-63.
  17. Choi SM, Kim Y, Shim JS, Park JT, Wang RH, Leach SD, Liu JO, Deng CX, Ye Z, Jang YY. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology, 2013; 57(6):2458-68.
  18. Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, Jaffee E, Hruban RH, Jinnah HA, Roden RB, Jimeno A, Liu JO, Maitra A, Eshleman JR. Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res, 2013; 19(5):1139-46.
  19. Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R and Liu JO. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst, 2012; 104(20):1576-90.
  20. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D. Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP. Gene Dev, 2012; 26(12): 1300-1305.
  21. Rovira M, Huang W, Yusuff S, Shim JS, Ferrante AA, Liu JO and Parsons MJ. Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation. Proc Natl Acad Sci USA, 2011; 108(48): 19264-19269.
  22. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E and Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov, 2011; 1(1): 68-77, Inaugural Issue.
  23. Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A and Liu JO. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst, 2010; 102(24): 1855-1873.
  24. Shim JS, Park HM, Lee J and Kwon HJ. Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. Biochem Biophys Res Comm, 2008; 371(1): 99-103.
  25. Shim JS, Lee HK, Park HM, Kim JO, Kim EK, Hwang KH, Kim KT, Park SH, Lee JH, and Kwon HJ. Development of an angiogenesis-focused cDNA chip and validation of its functionality. Exp Mol Med, 2005; 37(4): 365-370.
  26. Shim JS and Kwon HJ. Chemical genetics for therapeutic target mining. Expert Opin Ther Targets, 2004; 8(6): 653-661. (Review).
  27. Shim JS, Lee J, Park HJ, Park SJ, and Kwon HJ. A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. Chem Biol, 2004; 11: 1455-1463.
  28. Shim JS, Kim DH, and Kwon HJ. Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Oncogene, 2004; 23(9): 1704-1711.
  29. Shim JS, Lee HS, Shin J, and Kwon HJ. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett, 2004; 203(2):163-169.
  30. Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Park HJ, Shim BS, Choi SH, and Kwon HJ. Irreversible inhibition of CD13/aminopeptidase N by the anti-angiogenic agent curcumin. Chem Biol, 2003; 10: 695-704.
International patent: WO/2010/042163 – Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders. Liu JO, Shim JS, Chong CR, and Bhat S. 04/15/2010
Korea patent: 1006410760000 – A novel aminopeptidase N Inhibitor. Kwon HJ, Lee J and Shim JS. 10/25/2006
Korea patent: 1006046970000 – A novel calmodulin antagonist and an immunosuppressive agent comprising thereof. Kwon HJ, Shim JS and Lee J. 07/19/2006
International patent: WO/2003/105751 – Novel curcumin derivatives. Kwon HJ, Shim JS, Kim JH, Choi SH, Shin JH and Rho JR. 12/24/2003
06/25/2011Young Investigator Award in “2011 KSEA/KASBP Northeast Regional Conference and Bio Fair”, Edison, NJ, USA
05/25/2004Best Poster Award in “The 61st Annual Meeting 2004” of the Korean Society for Biochemistry and Molecular Biology, Seoul, Korea
10/18/2001Best Poster Award in “The Annual Meeting 2001” of the Korean Society for Biochemistry and Molecular Biology, Seoul, Korea
Professional Activities
2010-presentMember of the American Chemical Society (ACS)
2011-2012Vice President of the Baltimore Life Scientist Association (BLSA)
2011-2013Member of the Korean-American Scientists and Engineers Association (KSEA)
2011-2013Member of the Korean-American Professional Community in Biotechnology and Pharmaceuticals (KASBP)